Literature DB >> 16033327

Toll-like receptors and chronic lung disease.

Nazia Chaudhuri1, Steven K Dower, Moira K B Whyte, Ian Sabroe.   

Abstract

TLRs (Toll-like receptors) comprise a family of proteins whose function is principally to facilitate the detection of, and response to, pathogens. Protozoa, helminths, viruses, bacteria and fungi can all activate TLR signalling, and these signals have important roles in the activation of host defence. TLRs may also respond to products of tissue damage, providing them with roles in infective and sterile inflammation. Their role as detectors of pathogens and pathogen-associated molecules provides molecular mechanisms to underpin the observations leading to the hygiene hypothesis. Targeting of TLR signalling has implications in the control of infection, vaccine design, desensitization to allergens and down-regulation of inflammation. This review will explore TLR history, molecular signalling and the potential roles of TLRs in chronic lung disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033327     DOI: 10.1042/CS20050044

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  25 in total

1.  Impaired inflammatory responses to multiple toll-like receptor ligands in alveolar macrophages of streptozotocin-induced diabetic mice.

Authors:  Hideaki Yamasawa; Masayuki Nakayama; Masashi Bando; Yukihiko Sugiyama
Journal:  Inflamm Res       Date:  2012-01-07       Impact factor: 4.575

2.  Spatiotemporal inhibition of innate immunity signaling by the Tbc1d23 RAB-GAP.

Authors:  Lesly De Arras; Ivana V Yang; Brad Lackford; David W H Riches; Rytis Prekeris; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

Review 3.  Hyaluronan fragments as mediators of inflammation in allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Immunobiology       Date:  2014-12-31       Impact factor: 3.144

4.  Apoptosis Resistance in Fibroblasts Precedes Progressive Scarring in Pulmonary Fibrosis and Is Partially Mediated by Toll-Like Receptor 4 Activation.

Authors:  Kelly M Hanson; Eric B Hernady; Christina K Reed; Carl J Johnston; Angela M Groves; Jacob N Finkelstein
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

5.  Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions.

Authors:  Agnieszka Jezierska; Irina A Kolosova; Alexander D Verin
Journal:  Curr Signal Transduct Ther       Date:  2011

6.  Toll-like receptor 2 gene polymorphisms Arg677Trp and Arg753Gln in chronic obstructive pulmonary disease.

Authors:  Stefan Pabst; Vildan Yenice; Martina Lennarz; Izabela Tuleta; Georg Nickenig; Adrian Gillissen; Christian Grohé
Journal:  Lung       Date:  2009-04-19       Impact factor: 2.584

7.  An evolutionarily conserved innate immunity protein interaction network.

Authors:  Lesly De Arras; Amara Seng; Brad Lackford; Mohammad R Keikhaee; Bruce Bowerman; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

8.  Signal relay by CC chemokine receptor 2 (CCR2) and formylpeptide receptor 2 (Fpr2) in the recruitment of monocyte-derived dendritic cells in allergic airway inflammation.

Authors:  Keqiang Chen; Mingyong Liu; Ying Liu; Chunyan Wang; Teizo Yoshimura; Wanghua Gong; Yingying Le; Lino Tessarollo; Ji Ming Wang
Journal:  J Biol Chem       Date:  2013-04-19       Impact factor: 5.157

Review 9.  Identifying novel spatiotemporal regulators of innate immunity.

Authors:  Francisco Victorino; Scott Alper
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

10.  Identification of innate immunity genes and pathways using a comparative genomics approach.

Authors:  Scott Alper; Rebecca Laws; Brad Lackford; Windy A Boyd; Paul Dunlap; Jonathan H Freedman; David A Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.